ArticleAntiviral research2015
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.
Article in Antiviral research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study
Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Phytochemicals against SARS-CoV as potential drug leads.Biomedical journal · 2021Pooled it
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- Homoharringtonine is highly effective against SARS-CoV-2: a potential first-line defense in future coronavirus epidemics.National science review · 2025Article
- Article
- A critical review on phytochemicals as antiviral medications for SARS-CoV-2 virus infection.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Antiviral activity of nitazoxanide against pseudorabies virus infectionFrontiers in veterinary science · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- Homoharringtonine: mechanisms, clinical applications and research progress.Frontiers in oncology · 2025Review
- Advancements in vaccine development and therapeutic approaches for severe fever with Thrombocytopenia Syndrome.Frontiers in cellular and infection microbiology · 2025Review
- Advancements in antiviral approaches against foot-and-mouth disease virus: a comprehensive review.Frontiers in veterinary science · 2025Review
- Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistantEmerging microbes & infections · 2024Article
- Article
- Pilot-Scale Screening of Clinically Approved Drugs to Identify Uridine Insertion/Deletion RNA Editing Inhibitors inACS infectious diseases · 2024Article
- AnJournal of virology · 2024Article
- Antiviral Chemotherapy in Avian Medicine-A Review.Viruses · 2024Review
- High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.Antiviral research · 2024Article
- Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Review
- Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review.Clinical case reports · 2023Article
- What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.Virology journal · 2023Review
- An overview on medicinal plants used for combating coronavirus: Current potentials and challenges.Journal of agriculture and food research · 2023Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the recent emergence of Middle East Respiratory Syndrome coronavirus in humans and the outbreak of devastating porcine epidemic diarrhea coronavirus in swine, therapeutic intervention is urgently needed. However, anti-coronavirus drugs currently are not available. In an effort to assist rapid development of anti-coronavirus drugs, here we screened the NIH Clinical Collection in cell culture using a luciferase reporter-expressing recombinant murine coronavirus. Of the 727 compounds screened, 84 were found to have a significant anti-coronavirus effect. Further experiments revealed that 51 compounds blocked virus entry while 19 others inhibited viral replication. Additional validation studies with the top 3 inhibitors (hexachlorophene, nitazoxanide and homoharringtonine) demonstrated robust anti-coronavirus activities (a reduction of 6 to 8log10 in virus titer) with an IC50 ranging from 11nM to 1.2μM. Furthermore, homoharringtonine and hexachlorophene exhibited broad antiviral activity against diverse species of human and animal coronaviruses. Since the NIH Clinical Collection consists of compounds that have already been through clinical trials, these small molecule inhibitors have a great potential for rapid development as anti-coronavirus drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.